Skip to content
Clinical Trials – home

Hospital Quironsalud Zaragoza

Verified siteinfo

Spain Paseo Renovales S/n, 50006 Zaragoza, Spain

  • 4 trials recruiting
  • Myelofibrosis · Gaucher's disease type I · Breast cancer
  • Adults and children

About Specializations

Hospital Quironsalud Zaragoza in Zaragoza, Spain specialises in clinical trials of conditions such as Myelofibrosis, Gaucher's disease type I, Breast cancer, Anaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Congenital, Hereditary, and Neonatal Diseases

The research program at Hospital Quironsalud Zaragoza focuses on rare genetic disorders, evaluating the safety and long‑term efficacy of enzyme replacement and substrate reduction strategies for conditions such as Fabry disease and Gaucher disease.

  • Enzyme replacement therapy evaluation
  • Substrate reduction therapy safety
  • Pediatric dosing strategies
  • Long‑term disease monitoring

Multidisciplinary clinicians collaborate to improve outcomes for patients with inherited metabolic diseases, offering access to innovative therapies within a dedicated haematology department.

Hemic and Lymphatic Diseases

In the haematology unit, investigators explore new treatment options for blood‑cancer and myeloproliferative disorders, including Chronic Myeloid Leukemia, Myelofibrosis and Polycythemia Vera. Trials aim to enhance disease control, reduce symptom burden, and improve survival.

  • Targeted kinase inhibition
  • Combination with JAK inhibitors
  • Spleen volume reduction strategies
  • Symptom burden improvement

With eight investigators overseeing fourteen active studies, the site provides patients access to cutting‑edge therapies while generating valuable safety and efficacy data.

Neoplasms

Oncology research at the centre evaluates novel antibody‑drug conjugates and endocrine combinations for HR‑positive, HER2‑low advanced breast cancer, seeking to extend progression‑free survival and offer new options for patients with limited treatment choices.

  • Antibody‑drug conjugate efficacy
  • Comparative endocrine therapy
  • Biomarker‑driven patient selection
  • Survival outcome analysis

The collaborative effort integrates haematology expertise with oncology specialists, fostering a comprehensive approach to cancer care at the Zaragoza hospital.

Nutritional and Metabolic Diseases

The department conducts trials to address iron deficiency, comparing oral formulations such as Sucrosomial® Iron and ferric maltol for rapid hemoglobin normalization and improved tolerability in affected individuals.

  • Oral iron absorption studies
  • Hemoglobin normalization outcomes
  • Tolerability comparison
  • Patient‑reported quality‑of‑life measures

By integrating metabolic research within its haematology services, Hospital Quironsalud Zaragoza offers patients evidence‑based options to manage nutritional disorders effectively.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Paseo Renovales S/n50006 ZaragozaSpain
Recruiting now
4 trials
Conditions studied
11
Partner status
Verified site

More sites in ZaragozaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

16 clinical trials

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Iron deficiency

Recruiting

Study comparing Sucrosomial Iron and ferric maltol treatment for women with iron deficiency

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmanutra S.p.A.

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
  • Sponsor:Telios Pharma Inc.

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Gaucher's disease type I

Not yet recruiting

Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1 Using Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Spur Therapeutics Limited

Gaucher's disease type I

Not yet recruiting

Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Prevail Therapeutics Inc.

Anaemia+1

Not recruiting

Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Kartos Therapeutics Inc.

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.